CC
ESPR icon

Carlson Capital’s Esperion Therapeutics ESPR Stock Holding History

Carlson Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-75,125
Closed -$6.14M – 319
2015
Q2 		$6.14M Buy
+75,125
New +$7.35M 0.07% 236

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Carlson Capital's ESPR Position: Q3 2015 in Review

Carlson Capital sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 75,125 shares — an estimated $6.14M sold.

Carlson Capital first reported a position in ESPR in Q2 2015 and held it in 1 quarter. The position peaked at $6.14M in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

  • Carlson Capital reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Carlson Capital sold 75,125 Esperion Therapeutics shares in Q3 2015, an estimated $6.14M.
  • Carlson Capital first reported a position in Esperion Therapeutics in Q2 2015 and held it in 1 quarter.
  • Carlson Capital's Esperion Therapeutics position peaked at $6.14M in Q2 2015.
  • 121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on Carlson Capital's 13F filing for Q3 2015, filed 16 Nov 2015.